Zecuity (sumatriptan) Migraine Patch: FDA Evaluating Risk of Burns and Scars

By :

New Ebola Vaccine for Exposure Risk

The U.S. Food and Drug Administration (FDA) is investigating the risk of serious burns and potential permanent scarring with the use of Zecuity (sumatriptan iontophoretic transdermal system) patch for migraine headaches. FDA is investigating the cause and extent of these serious side effects and will update the public with new information when review is complete. Patients who experience moderate to severe pain at the Zecuity patch site should immediately remove it to avoid possible burns or scarring, regardless of how long the patch has been worn, and contact your health care professional. Do not bathe, shower, or swim while wearing the patch. Read the Patient Information leaflet and the Instructions for Use section in the drug label, and talk with your health care professional if you have any questions or concerns. Health care professionals should advise patients who complain of moderate to severe pain at the application site to remove the Zecuity patch immediately. Consider a different formulation of sumatriptan or switch these patients to an alternative migraine medicine. Evaluate patients and the application site as needed. The Zecuity patch contains the active ingredient sumatriptan, a prescription medicine used to treat acute migraine headaches in adults. The patch delivery system is designed to deliver a dose of medicine by way of a single-use, battery-powered patch that is wrapped around the upper arm or thigh. It should remain in place for no longer than four hours. Since marketing of the Zecuity patch began in September 2015, a large number of patients have reported they experienced burns or scars on the skin where the patch was worn. The reports included descriptions of severe redness, pain, skin discoloration, blistering, and cracked skin. As a result, we are investigating these serious adverse events to determine whether future regulatory action is needed. Source : [06/02/2016 – Drug Safety Communication – FDA] For More Alerts #health #Migraine #safe #Drugalert #FDA #Prevent #prevention #Alert #healthcare #drug #Safety #lifestyle
Rate UsDon’t love itNot greatGoodGreatLove itRate Us
Your opinion
arrow&v
arrow&v

PHAF Team

Using cosmetics during pregnancy may harm your child

PHAF Team

FDA approves first generic Crestor

PHAF Team

More than 300 fixed-dose combinations banned by Health Ministry (India)

PHAF Team

Vit. D overdose: lead to death of child

PHAF Team

FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease

PHAF Team

Small amount of chocolate each day may prevent diabetes

© 2019 PHAF  || All rights reserved

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon

Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.